Compare · COAG vs TAK

COAG vs TAK

Side-by-side comparison of Hemab Therapeutics Holdings Inc. (COAG) and Takeda Pharmaceutical Company Limited (TAK): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. COAG focuses on Biotechnology: Biological Products (No Diagnostic Substances), while TAK focuses on Biotechnology: Pharmaceutical Preparations.
  • TAK is the larger of the two at $68.79B, about 37.5x COAG ($1.84B).
  • COAG has been more active in the news (8 items in the past 4 weeks vs 6 for TAK).
  • TAK has more recent analyst coverage (6 ratings vs 0 for COAG).
MetricCOAGTAK
Company
Hemab Therapeutics Holdings Inc.
Takeda Pharmaceutical Company Limited
Price
-
-
Market cap
$1.84B
$68.79B
1M return
+12.43%
-
1Y return
+14.40%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2026
2018
News (4w)
8
6
Recent ratings
0
6
COAG

Hemab Therapeutics Holdings Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

TAK

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Latest COAG

Latest TAK